Newsletter December 2020

2020 has been a difficult year for everyone. However, despite the many…

Por Lucie van Leeuwen.Publicado January 6, 2021
Newsletter December 2020

2020 has been a difficult year for everyone. However, despite the many challenges, we can also look back on some milestone achievements. In our latest newsletter, we review some of our major highlights. Click the link to read our newsletter: http://bit.ly/3njT6nQ

Would you like to receive our next newsletter in your email? You can subscribe here: https://www.tricals.org/subscribe-to-our-newsletter/

We look forward to the new year in which we will undoubtedly achieve even more together. Together we will build our highway towards new therapies for ALS.


Compartir

Noticias relacionadas

Amylyx withdraws RELYVRIO/AMX0035 from U.S. and Canadian markets
Amylyx withdraws RELYVRIO/AMX0035 from U.S. and Canadian markets
Yesterday, the pharmaceutical company Amylyx announced that they are withdrawing the drug […]
Results of TUDCA-study: No effect of investigated compound
Results of TUDCA-study: No effect of investigated compound
The TUDCA-ALS consortium has announced the first findings of the TUDCA study, […]
Amylyx: no effect after analyzing phase 3 study
Amylyx: no effect after analyzing phase 3 study
The pharmaceutical company Amylyx announced the first results of the PHOENIX study. […]
Tofersen receives positive opinion from CHMP (EMA)
Tofersen receives positive opinion from CHMP (EMA)
The Committe of Medicinal Products for Human Use (CHMP) of the European […]